159 related articles for article (PubMed ID: 18517234)
1. NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics.
Natarajan A; Gruettner C; Ivkov R; DeNardo GL; Mirick G; Yuan A; Foreman A; DeNardo SJ
Bioconjug Chem; 2008 Jun; 19(6):1211-8. PubMed ID: 18517234
[TBL] [Abstract][Full Text] [Related]
2. Development of multivalent radioimmunonanoparticles for cancer imaging and therapy.
Natarajan A; Xiong CY; Gruettner C; DeNardo GL; DeNardo SJ
Cancer Biother Radiopharm; 2008 Feb; 23(1):82-91. PubMed ID: 18298332
[TBL] [Abstract][Full Text] [Related]
3. Development of tumor targeting bioprobes ((111)In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy.
DeNardo SJ; DeNardo GL; Miers LA; Natarajan A; Foreman AR; Gruettner C; Adamson GN; Ivkov R
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7087s-7092s. PubMed ID: 16203807
[TBL] [Abstract][Full Text] [Related]
4. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
5. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
[No Abstract] [Full Text] [Related]
6. Cellular level loading and heating of superparamagnetic iron oxide nanoparticles.
Kalambur VS; Longmire EK; Bischof JC
Langmuir; 2007 Nov; 23(24):12329-36. PubMed ID: 17960940
[TBL] [Abstract][Full Text] [Related]
7. Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in mice.
DeNardo SJ; DeNardo GL; Natarajan A; Miers LA; Foreman AR; Gruettner C; Adamson GN; Ivkov R
J Nucl Med; 2007 Mar; 48(3):437-44. PubMed ID: 17332622
[TBL] [Abstract][Full Text] [Related]
8. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A
Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653
[TBL] [Abstract][Full Text] [Related]
9. Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles.
Beduneau A; Ma Z; Grotepas CB; Kabanov A; Rabinow BE; Gong N; Mosley RL; Dou H; Boska MD; Gendelman HE
PLoS One; 2009; 4(2):e4343. PubMed ID: 19183814
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, characterization and theranostic evaluation of Indium-111 labeled multifunctional superparamagnetic iron oxide nanoparticles.
Zolata H; Abbasi Davani F; Afarideh H
Nucl Med Biol; 2015 Feb; 42(2):164-70. PubMed ID: 25311750
[TBL] [Abstract][Full Text] [Related]
11. The fate of MAb-targeted Cd(125m)Te/ZnS nanoparticles in vivo.
Kennel SJ; Woodward JD; Rondinone AJ; Wall J; Huang Y; Mirzadeh S
Nucl Med Biol; 2008 May; 35(4):501-14. PubMed ID: 18482688
[TBL] [Abstract][Full Text] [Related]
12. Triple Therapy of HER2
Zolata H; Afarideh H; Davani FA
Cancer Biother Radiopharm; 2016 Nov; 31(9):324-329. PubMed ID: 27831759
[TBL] [Abstract][Full Text] [Related]
13. Effects of linker chemistry on the pharmacokinetics of radioimmunoconjugates.
Quadri SM; Vriesendorp HM
Q J Nucl Med; 1998 Dec; 42(4):250-61. PubMed ID: 9973840
[TBL] [Abstract][Full Text] [Related]
14. Development of anti-HER2 fragment antibody conjugated to iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging.
Kanazaki K; Sano K; Makino A; Shimizu Y; Yamauchi F; Ogawa S; Ding N; Yano T; Temma T; Ono M; Saji H
Nanomedicine; 2015 Nov; 11(8):2051-60. PubMed ID: 26238078
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of
Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
[TBL] [Abstract][Full Text] [Related]
16. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
[TBL] [Abstract][Full Text] [Related]
17. Targeted cell uptake of a noninternalizing antibody through conjugation to iron oxide nanoparticles in primary central nervous system lymphoma.
Wang T; Kievit FM; Veiseh O; Arami H; Stephen ZR; Fang C; Liu Y; Ellenbogen RG; Zhang M
World Neurosurg; 2013; 80(1-2):134-41. PubMed ID: 23298674
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for pancreatic cancer.
Dobiasch S; Szanyi S; Kjaev A; Werner J; Strauss A; Weis C; Grenacher L; Kapilov-Buchman K; Israel LL; Lellouche JP; Locatelli E; Franchini MC; Vandooren J; Opdenakker G; Felix K
J Nanobiotechnology; 2016 Dec; 14(1):81. PubMed ID: 27993133
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor-bearing mice.
DeNardo SJ; Zhong GR; Salako Q; Li M; DeNardo GL; Meares CF
J Nucl Med; 1995 May; 36(5):829-36. PubMed ID: 7738660
[TBL] [Abstract][Full Text] [Related]
20. Effects of iron oxide nanoparticles on biological responses and MR imaging properties in human mammary healthy and breast cancer epithelial cells.
Zhang Q; Rajan SS; Tyner KM; Casey BJ; Dugard CK; Jones Y; Paredes AM; Clingman CS; Howard PC; Goering PL
J Biomed Mater Res B Appl Biomater; 2016 Jul; 104(5):1032-42. PubMed ID: 26013845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
